Just remember that valuation from years ago was based on SequestOx and that IP succeeding and creating “treadmill” of products to fill pipeline and launch with branded drugs.
This is a completely different company focused on generics that have lower profitability, more competition and will yield lower forward industry multiple.
I can’t see Nasrat needing to pursue another valuation, but rather expect him to let the markets do their job as company progresses launching and filing new products, improving financials, etc. Looking forward to seeing what products are going to fill pipeline after last CNS gets filed (assuming next year).
News 
Market Data 
Discover 
